证券代码：300254 证券简称：仟源医药 公告编号：2023-071 山西仟源医药集团股份有限公司 关于公司盐酸舍曲林片通过仿制药一致性评价的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 山西仟源医药集团股份有限公司（以下简称"公司"）近日收到了国家药品 监督管理局核准签发的"盐酸舍曲林片"的《药品补充申请批准通知书》，该药 品已通过仿制药质量与疗效一致性评价，现将相关情况公告如下： 一、药品基本情况 药品通用名称：盐酸舍曲林片 药品标准：YBH13312023 原药品批准文号：国药准字H20060316 英文名/拉丁名：Sertraline Hydrochloride Tablets 剂型：片剂 注册分类：化学药品 规格：50mg 公司盐酸舍曲林片用于治疗抑郁症的相关症状，包括伴随焦虑、有或无躁狂 史的抑郁症；也用于治疗强迫症。该品种现已列入国家医保目录。目前包括公司 在内已有5家企业通过仿制药质量和疗效一致性评价。 三、对公司的影响及风险提示 根据国家相关政策，通过仿制药质量与疗效一致性评价的药品品种，在药 品招标、医保支付层面等方面获得一定支持 ...

太平洋证券股份有限公司 关于山西仟源医药集团股份有限公司 2023 年半年度持续督导跟踪报告 | 保荐人名称：太平洋证券股份有限公司 | 被保荐公司简称：仟源医药 | | --- | --- | | 保荐代表人姓名：欧阳凌 | 联系电话：021-61376535 | | 保荐代表人姓名：杨竞 | 联系电话：010-88321518 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于防止关联方 | | | 占用公司资源的制度、募集资金管理制度、内控制度、内部审计 | 是 | | 制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6 次 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4.公司治理督导 ...

证券代码： 300254 证券简称：仟源医药 山西仟源医药集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|---------------|----------------------------| | 投资者关系活动 | √特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | 参与单位名称及 人员姓名 三足基金：李功锋 时间 11:45-12:15 地点 公司上海办公室 上市公司接待人 员姓名 董秘：俞俊贤 1、公司连续亏损，今年从公司经营角度有没有好转的预 期？ 答：这几年公司受注射用美洛西林钠舒巴坦钠等重点产 品退出医保、部分产品未集采中标，计提金融负债财务费用、 计提各项资产减值准备等因素的影响，出现了连续亏损。随 着公司新产品的上市，计提金融负债财务费用的减少，闲置 投资者关系活动 资产出售等，未来公司经营业绩会有所改善。 主要内容介绍 2、公司财务费用较高的原因？ 答：公司这几年财务 ...

山西仟源医药集团股份有限公司2023年半年度报告全文 山西仟源医药集团股份有限公司 2023 年半年度报告 ...

证券代码：300254 证券简称：仟源医药 公告编号：2023-032 特此公告 山西仟源医药集团股份有限公司 董事会 山西仟源医药集团股份有限公司 关于参加山西辖区上市公司2023年 投资者网上集体接待日暨年报业绩说明会的公告 二〇二三年五月五日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，山西仟源医药集团股份有限公司（以下 简称"公司"）将参加由中国证券监督管理委员会山西监管局、山西省上市公司 协会与深圳市全景网络有限公司联合举办的"山西辖区上市公司 2023 年投资者 网上集体接待日暨年报业绩说明会活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演APP, 参与本次互动交流，活动时间为2023年5月11日（周四）15:00-17:00。 届时公司总裁赵群先生、董事会秘书俞俊贤先生、财务总监贺延捷先生以及 相关工作人员将在线就公司2022年度业绩、公司治理、发展战略、经营状况等投 资者关心的问题 ...

Financial Performance - The company's revenue for Q1 2023 was ¥183,185,038.02, a decrease of 4.46% compared to ¥191,735,280.29 in the same period last year[5] - The net loss attributable to shareholders was ¥2,156,812.13, representing a 40.00% increase in losses from ¥1,540,598.15 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 183,185,038.02, a decrease of 4.06% compared to CNY 191,735,280.29 in Q1 2022[23] - Net profit for Q1 2023 was CNY 2,981,088.59, a decline from CNY 3,850,295.44 in Q1 2022[24] - The total comprehensive income for the period was CNY 2,981,088.59, compared to CNY 3,850,295.44 in the previous period[25] - The company's basic and diluted earnings per share were both -¥0.0089, a decrease of 30.88% from -¥0.0068 in the same period last year[5] - The company reported a basic and diluted earnings per share of CNY -0.0089, compared to CNY -0.0068 in the previous period[25] Cash Flow and Liquidity - The net cash flow from operating activities was -¥6,564,702.62, a decline of 120.37% compared to a positive cash flow of ¥32,222,075.16 in the previous year[5] - The company reported a net cash flow from operating activities of CNY -6,564,702.62, a significant decrease from CNY 32,222,075.16 in the previous period[28] - Cash inflow from operating activities totaled CNY 195,669,573.00, down from CNY 237,810,837.66 year-over-year[27] - The balance of cash and cash equivalents at the end of the reporting period was ¥343,318,600, an increase of 30.07% due to the receipt of a ¥100,000,000 performance bond from asset sales[9] - The company reported a cash balance of CNY 343,318,562.95 as of March 31, 2023, up from CNY 263,945,639.30 at the beginning of the year, indicating a growth of approximately 30.1%[20] - Cash and cash equivalents at the end of the period amounted to CNY 341,918,562.95, an increase from CNY 114,720,149.01 at the end of the previous period[28] - The net cash flow from investing activities was CNY 94,530,117.73, a turnaround from CNY -8,937,432.09 in the previous period[28] - The total cash outflow from financing activities was CNY 10,892,491.46, compared to CNY 12,169,773.54 in the previous period[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,644,516,932.21, an increase of 3.80% from ¥1,584,324,080.78 at the end of the previous year[5] - The company's total assets increased to CNY 1,644,516,932.21 in Q1 2023, up from CNY 1,584,324,080.78 in Q1 2022[22] - Total liabilities rose to CNY 911,856,123.42 in Q1 2023, compared to CNY 854,644,360.58 in the previous year[22] - The balance of prepayments decreased by 39.02% to ¥13,088,600, primarily due to reduced advance payments for goods[9] - Other non-current assets increased by 142.45% to ¥2,246,200, mainly due to increased advance payments for long-term asset purchases[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,008[13] - The total number of restricted shares at the end of the period was 17,985,699, with no shares released during the reporting period[16] - The top ten unrestricted shareholders hold a total of 50,000,000 shares, with the largest shareholder holding 15,772,409 shares[14] Strategic Initiatives - The company completed the election of the fifth board of directors and management team, appointing key personnel including Huang Lequn as chairman and Zhao Qun as president[17] - The subsidiary Jiangsu Jiayi Pharmaceutical Co., Ltd. received drug registration certificates for two new products, indicating ongoing product development efforts[17] - The company signed an asset sale framework agreement with Shanxi Shuangyan Pharmaceutical Co., Ltd. to optimize asset structure and reduce operational costs[18] - The company’s subsidiary Sichuan Qianyuan Traditional Chinese Medicine Co., Ltd. received a high-tech enterprise certificate, enhancing its market position[18] - The company aims to centralize production to lower costs and improve profitability, aligning with its strategic goals[18] - The company’s financial strategy includes avoiding large-scale fixed asset investments while enhancing operational efficiency through asset optimization[18] Operating Costs and Expenses - Total operating costs for Q1 2023 were CNY 185,981,096.81, down 7.26% from CNY 200,523,656.60 in the same period last year[23] - The company reported a decrease in sales expenses to CNY 76,345,934.29 in Q1 2023, down from CNY 94,256,873.49 in Q1 2022[23] - Research and development expenses for Q1 2023 were CNY 8,927,664.99, a decrease of 5.5% from CNY 9,449,694.89 in Q1 2022[24]

Financial Performance - The net profit attributable to shareholders for the year was -118.5746 million yuan, primarily impacted by the failure of Ebastine tablets to win the national centralized procurement bid in Q4 2022, leading to a 10.9% year-over-year decline in operating revenue[5]. - The company's operating revenue for 2022 was ¥828,997,054.54, a decrease of 10.90% compared to ¥930,374,948.87 in 2021[24]. - The net profit attributable to shareholders was -¥118,574,644.28, representing a decline of 29.68% from -¥91,437,557.03 in the previous year[24]. - The cash flow from operating activities was ¥74,876,116.47, down 22.75% from ¥96,921,058.52 in 2021[24]. - The basic and diluted earnings per share were both -¥0.5002, a decrease of 24.71% from -¥0.4011 in 2021[24]. - The net cash flow from operating activities decreased by 22.75% to ¥74,876,116.47 compared to the previous year[65]. - The net cash flow from financing activities increased significantly by 173.91% to ¥112,563,796.19, primarily due to funds raised from a simplified refinancing process[65]. - The total cash and cash equivalents increased by 303.82% to ¥164,240,359.82, reflecting improved liquidity[65]. - The company reported a total distributable profit of 0.00 yuan, with no cash dividends or stock bonuses proposed for the 2022 fiscal year[142]. - The cash dividend amount, including other methods, was also reported as 0.00 yuan, indicating no distribution to shareholders[142]. Strategic Focus and Development - The company is focusing on the development of new products and technologies, although specific details were not provided in the report[5]. - The company is exploring potential mergers and acquisitions to enhance its market position, although no specific targets were disclosed[5]. - The company is committed to enhancing its research and development capabilities to meet the growing demand for health products and improve product competitiveness[35]. - The company aims to focus on high-end drug research and development, transitioning from generic drugs to high-quality generics, and plans to enhance its core competitiveness through increased R&D efforts[93]. - The company plans to enhance sales by focusing on new product launches and optimizing existing product strategies, with an emphasis on expanding the OTC market and improving online sales efficiency[94]. - The company plans to increase R&D efficiency and accelerate new product development, with a focus on high-difficulty generic projects and innovative drug research[94]. Market Environment and Challenges - The pharmaceutical industry faced a complex external environment in 2022, with a 1.6% decline in revenue and a 31.8% drop in total profit for the industry[33]. - The decline in revenue was primarily due to the failure of Ebasitine tablets to win the national centralized procurement bid, significantly impacting Q4 2022 results[40]. - The company continues to face uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profits over the last three years[24]. - The company faces risks from industry policy changes, including drug price reductions and potential exits from the National Medical Insurance Directory, which could significantly impact revenue[96][98]. - Rising raw material costs pose a risk, prompting the company to implement lean production practices to improve efficiency and reduce costs[99]. Governance and Compliance - The company strictly adheres to the requirements of the Company Law and relevant regulations, ensuring compliance in corporate governance and enhancing information disclosure practices[103]. - The board of directors has established four specialized committees, including the Innovation and Strategy Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee, to provide professional opinions for decision-making[104]. - The company has a complete and independent financial institution, with a robust accounting system and independent financial decision-making capabilities[109]. - The board approved the adjustment of the 2021 private placement plan for specific targets[125]. - The company emphasized the importance of considering the interests of minority shareholders in decision-making processes[129]. Human Resources and Talent Development - The total number of employees at the end of the reporting period was 1,217, including 458 at the parent company and 759 at major subsidiaries[135]. - The company emphasizes talent introduction and training, continuously improving training mechanisms to enhance employee skills[138]. - The company has established a salary policy that matches job value and performance, enhancing employee motivation and satisfaction[137]. - The company has 54 employees with a postgraduate degree or above, 340 with a bachelor's degree, 403 with a diploma, and 420 with a high school education or below[135]. Environmental Responsibility - The company strictly adheres to environmental protection laws and standards, confirming compliance with various national and local regulations[150]. - The company invested 1.2365 million yuan in environmental governance and protection in 2022[155]. - The concentration of ammonia nitrogen in wastewater was reduced to 458 mg/L, with a total discharge of 2 tons/year[152]. - The company has implemented an online monitoring system for chemical oxygen demand, ammonia nitrogen, flow, and pH at the wastewater discharge outlet[155]. - The company has established a comprehensive emergency response plan for environmental incidents, filed with the local ecological environment bureau[154]. Financial Management and Fundraising - The company raised RMB 110 million through a private placement of shares in May 2022, aimed at optimizing product structure and enhancing R&D capabilities[51]. - The company plans to use RMB 11,500 million from the 2020 fundraising to increase capital in its subsidiary, Qianyuan Baoling[78]. - The company has committed to invest RMB 25,000 million in various projects, with RMB 12,238 million already utilized by the end of the reporting period[81]. - The company has significant assets pledged for bank loans, totaling ¥710,563,168.94, indicating a reliance on external financing[72]. - The company has not made any major acquisitions or disposals of assets during the reporting period[172].

Group 1: Company Operations - The company operates in gene preservation and prenatal environment testing through self-operated and agency models, with a team of approximately 50 people established for sample hospitals across multiple provinces [2] - The company aims to exceed 500 hospitals covered by signed distributors nationwide this year, having already surpassed 200 [3] - The current price for gene preservation is 4,960 yuan per case, with a high gross profit margin [3] Group 2: Investment and Partnerships - The company has invested in a new drug research and development company and is preparing to discuss another investment in a small RNA innovative drug company [4] - The company has not yet engaged with state-owned pharmaceutical enterprises regarding reform [4] - The acquisition of Sichuan Guanghan Traditional Chinese Medicine Co., Ltd. was driven by the potential for development in the traditional Chinese medicine sector and the opportunity to create products related to maternal and infant health [4] Group 3: Financial Activities - The funds for the non-public issuance of shares are in place, pending approval from the China Securities Regulatory Commission for the issuance plan [3]

证券代码：300254 证券简称：仟源医药 山西仟源医药集团股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | --- | --- | --- | --- | |-----------------------------|-----------------------------------|---------------------------------------------------------------------------------|------------------------------------------|--------|-------|------------------| | | | | | | | | | | | □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | | | | | 投资者关系活动 | □新闻发布会 | □路演活动 | | | | | | 类别 | □现场参观 √其他（ 2022 | | 年山西辖区上市公司投资者网上集体接待日暨 | | | | | 参与单位名称 | 年报业绩说明会） 线上参与 2 ...

Financial Performance - The company's revenue for Q3 2022 was ¥228,896,813.46, a decrease of 11.84% compared to the same period last year[5] - The net profit attributable to shareholders was -¥2,546,073.37, representing a decline of 100.65% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥5,020,360.17, down 43.26% from the previous year[5] - Total operating revenue for Q3 2022 was CNY 633.85 million, a decrease of 11.7% compared to CNY 717.45 million in Q3 2021[23] - The net profit for Q3 2022 was a loss of CNY 2.87 million, compared to a profit of CNY 6.64 million in Q3 2021[24] - The company reported a loss attributable to shareholders of CNY 25.37 million in Q3 2022, compared to a loss of CNY 5.39 million in the previous year[24] - The company reported a total comprehensive loss of CNY 2.87 million for Q3 2022, compared to a comprehensive income of CNY 6.64 million in the same quarter last year[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,648,939,537.32, an increase of 8.00% compared to the end of the previous year[5] - Total assets increased to CNY 1.65 billion in Q3 2022, up from CNY 1.53 billion in Q3 2021, reflecting a growth of 8.0%[22] - Total liabilities rose to CNY 848.14 million in Q3 2022, compared to CNY 782.23 million in Q3 2021, marking an increase of 8.4%[22] - The company's total current assets increased to ¥523,907,396.16 from ¥375,891,284.85 at the beginning of the year, representing a growth of approximately 39.3%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,562[12] - The top shareholder, Weng Zhangguo, holds 15,772,409 shares, representing 6.53% of total shares[12] - Zhao Qun, the second-largest shareholder, holds 13,401,892 shares, which is 5.55% of total shares, with 10,051,419 shares under lock-up[12] - The total number of unrestricted shares held by the top ten shareholders includes 15,772,409 shares from Weng Zhangguo and 10,000,000 shares from Shanghai Tongyi Investment Management[12] - The company has not disclosed any relationships or concerted actions among the top ten unrestricted shareholders[12] Cash Flow - The cash flow from operating activities for the year-to-date was ¥61,939,568.65, a decrease of 19.54%[5] - The cash inflow from operating activities for the current period was ¥689,602,195.84, a decrease of 14.3% compared to ¥804,665,843.06 in the previous period[25] - The net cash flow from operating activities was ¥61,939,568.65, down 19.6% from ¥76,981,749.49 in the previous period[25] - The cash inflow from financing activities was ¥327,949,994.52, significantly higher than ¥62,880,000.00 in the previous period[26] - The net cash flow from financing activities was ¥133,646,525.75, improving from -¥108,492,628.30 in the previous period[26] Investments and Expenses - Research and development expenses for Q3 2022 were CNY 36.54 million, a decrease of 11.8% from CNY 41.28 million in Q3 2021[23] - The company terminated the project for the production line upgrade at Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd., reallocating the remaining fundraising of ¥6,560.53 million to supplement working capital permanently[17][18] - Long-term equity investments slightly decreased to ¥89,157,335.35 from ¥90,923,391.56, a reduction of about 1.9%[20] - The company's fixed assets decreased to ¥293,108,187.91 from ¥300,260,615.40, showing a decline of approximately 2.4%[20] - The company's inventory increased slightly to ¥109,723,545.83 from ¥108,384,753.42, indicating a growth of about 1.2%[20]